autologous CMV-specific cytotoxic T-lymphocytes

Autologous CMV-specific cytotoxic T-lymphocytes (CTLs) are a cell-based immunotherapy developed by Baylor College of Medicine for the treatment of cytomegalovirus (CMV)-positive glioblastoma multiforme (GBM). The therapy involves harvesting peripheral blood mononuclear cells (PBMCs) from the patient, which are then stimulated with CMV antigens, specifically pp65 and IE1, using adenoviral vectors. These stimulated T cells (both CD4+ and CD8+) are expanded in vitro and reinfused intravenously. The mechanism of action relies on the T cells' ability to recognize and eliminate GBM cells that express CMV antigens, which are frequently found in these tumors but not in healthy brain tissue. This approach aims to leverage the immune system to target viral components within the tumor microenvironment to improve outcomes in patients with recurrent or refractory GBM.

Other names

CMV-specific T cellsCMV-specific CTLsCMV-T cellsCMV-VSTs